RU2004136574A - Транскрипционная регуляторная днк гена хомяка ef-1 - Google Patents

Транскрипционная регуляторная днк гена хомяка ef-1 Download PDF

Info

Publication number
RU2004136574A
RU2004136574A RU2004136574/13A RU2004136574A RU2004136574A RU 2004136574 A RU2004136574 A RU 2004136574A RU 2004136574/13 A RU2004136574/13 A RU 2004136574/13A RU 2004136574 A RU2004136574 A RU 2004136574A RU 2004136574 A RU2004136574 A RU 2004136574A
Authority
RU
Russia
Prior art keywords
dna
host cell
protein
chimeric polynucleotide
hamster
Prior art date
Application number
RU2004136574/13A
Other languages
English (en)
Inventor
Дэниэл С ЭЛЛИСОН (US)
Дэниэл С ЭЛЛИСОН
Original Assignee
Айкос Корпорейшен (Us)
Айкос Корпорейшен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айкос Корпорейшен (Us), Айкос Корпорейшен filed Critical Айкос Корпорейшен (Us)
Publication of RU2004136574A publication Critical patent/RU2004136574A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Claims (15)

1. Очищенная и выделенная транскрипционная регуляторная ДНК гена хомяка EF-1α, выбранная из группы, состоящей из
a) ДНК, включающей приблизительно 1,56kb 5' к стартовому кодону ATG в SEQ ID NO:1; и
b) последовательность ДНК, которая гибридизируется с ДНК, представленной в SEQ ID NO:1 в условиях, которые включают конечную промывку при 65°С в буфере, содержащем примерно 2х SSC и примерно 0,1% SDS.
2. ДНК по п.1, где указанная ДНК неоперативно связана с кодирующими последовательностями EF-1α и способна трансформировать или трансфицировать клетку-хозяина.
3. Клонирующий вектор, включающий в себя ДНК по п.1, где указанная ДНК неоперативно связана с кодирующими последовательностями EF-1α, где указанный вектор способен трансформировать или трансфицировать клетку-хозяина.
4. Химерный полинуклеотид, включающий в себя регуляторную ДНК по п.1, оперативно связанную с кодирующей белок последовательностью ДНК, причем указанная кодирующая белок последовательность ДНК кодирует белок, отличный от EF-1α хомяка.
5. Химерный полинуклеотид по п.4, где указанная кодирующая белок последовательность ДНК кодирует белок, эндогенный к клеткам хомяка, отличным от EF-1α.
6. Химерный полинуклеотид по п.4, где последовательность ДНК кодирует белок, гетерологичный к клеткам хомяка.
7. Химерный полинуклеотид по любому из пп.4-6, где указанный полинуклеотид способен трансформировать или трансфицировать клетку-хозяина.
8. Экспрессионная плазмида, включающая в себя химерный полинуклеотид по любому из пп.4-6, где указанная плазмида способна трансформировать или трансфицировать клетку-хозяина животного.
9. Экспрессионная плазмида по п.8, дополнительно включающая в себя последовательность нуклеиновой кислоты, изложенную в SEQ ID NO:28.
10. Экспрессионная плазмида по п.9, где последовательность нуклеиновой кислоты согласно SEQ ID NO:28 расположена 3' относительно химерного полинуклеотида.
11. Способ увеличения транскрипции желаемого гена в клетке-хозяине, включающий в себя этап интегрирования ДНК, содержащей регуляторную ДНК гена хомяка EF-1α по п.1 в геномную ДНК указанной клетки-хозяина в положении, оперативно связанном с желаемым геном.
12. Способ по п.11, где указанная ДНК, подлежащая интеграции, дополнительно включает в себя последовательность-мишень.
13. Способ по п.11, где клетка-хозяин является клеткой яичника китайского хомяка.
14. Способ по п.13, где желаемый ген является эндогенным по отношению к клетке-хозяину яичника китайского хомяка.
15. Способ по п.11, где желаемый ген является гетерологичным по отношению к клеткам яичника китайского хомяка и устойчиво интегрируется в геномную ДНК клеток яичника китайского хомяка.
RU2004136574/13A 1997-05-01 2004-12-10 Транскрипционная регуляторная днк гена хомяка ef-1 RU2004136574A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/847,218 US5888809A (en) 1997-05-01 1997-05-01 Hamster EF-1α transcriptional regulatory DNA
US08/847,218 1997-05-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU99101788/13A Division RU2249617C2 (ru) 1997-05-01 1998-05-01 ТРАНСКРИПЦИОННАЯ РЕГУЛЯТОРНАЯ ДНК ГЕНА ХОМЯКА EF-1α

Publications (1)

Publication Number Publication Date
RU2004136574A true RU2004136574A (ru) 2006-05-27

Family

ID=25300098

Family Applications (2)

Application Number Title Priority Date Filing Date
RU99101788/13A RU2249617C2 (ru) 1997-05-01 1998-05-01 ТРАНСКРИПЦИОННАЯ РЕГУЛЯТОРНАЯ ДНК ГЕНА ХОМЯКА EF-1α
RU2004136574/13A RU2004136574A (ru) 1997-05-01 2004-12-10 Транскрипционная регуляторная днк гена хомяка ef-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU99101788/13A RU2249617C2 (ru) 1997-05-01 1998-05-01 ТРАНСКРИПЦИОННАЯ РЕГУЛЯТОРНАЯ ДНК ГЕНА ХОМЯКА EF-1α

Country Status (20)

Country Link
US (1) US5888809A (ru)
EP (2) EP1676916A1 (ru)
JP (1) JP2000513948A (ru)
CN (2) CN101570753A (ru)
AT (1) ATE318900T1 (ru)
AU (1) AU742561B2 (ru)
BR (1) BR9804896B1 (ru)
CZ (1) CZ296544B6 (ru)
DE (1) DE69833649T2 (ru)
DK (1) DK0920498T3 (ru)
ES (1) ES2263206T3 (ru)
HK (1) HK1022719A1 (ru)
HU (1) HU225764B1 (ru)
IL (1) IL127897A (ru)
NO (1) NO323853B1 (ru)
PL (1) PL195604B1 (ru)
PT (1) PT920498E (ru)
RU (2) RU2249617C2 (ru)
SK (1) SK285664B6 (ru)
WO (1) WO1998049289A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2535871C1 (ru) * 2013-07-10 2014-12-20 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") Плазмида для экспрессии в клетке китайского хомячка, клетка китайского хомячка - продуцент белка с Gla-доменом и способ получения белка с Gla-доменом

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
KR20000046969A (ko) * 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
MXPA03003207A (es) * 2000-10-12 2004-03-26 Icos Corp Materiales y metodos para modular la actividad de union de ligando/enzimatica de proteinas alfa/¦ que contienen un sitio regulador alosterico.
WO2002050264A2 (en) * 2000-12-18 2002-06-27 Wyeth Promoters and recombinant expression constructs
DE60236331D1 (de) * 2001-07-04 2010-06-17 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
WO2003106674A2 (en) * 2002-06-14 2003-12-24 Chromagenics B.V. Means and methods for regulating gene expression
ES2362273T3 (es) * 2002-06-14 2011-06-30 Chromagenics B.V. Método para la producción simultánea de múltiples proteínas; vectores y células para su uso en el mismo.
WO2004055215A1 (en) * 2002-12-18 2004-07-01 Chromagenics B.V. A method for improving protein production
DE60312039T2 (de) * 2002-12-20 2007-11-08 Chromagenics B.V. Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
ES2339710T5 (es) 2003-09-23 2017-10-05 University Of North Carolina At Chapel Hill Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K
US8999667B2 (en) * 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) * 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
JP5291341B2 (ja) * 2004-11-08 2013-09-18 クロマジェニックス ベー ヴェー タンパク質を高レベルで発現する宿主細胞の選定
ES2384391T3 (es) 2004-11-08 2012-07-04 Chromagenics B.V. Selección de células hospedantes que expresan proteína a altos niveles
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060121574A1 (en) * 2004-12-08 2006-06-08 Icos Corporation Recombinant method for making multimeric proteins
US20090325226A1 (en) * 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
EP2722051B1 (en) 2005-07-07 2018-11-07 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
BRPI0617688A2 (pt) 2005-10-21 2011-06-07 Hoffmann La Roche método para expressão recombinante de um polipeptìdeo
CA2624685C (en) 2005-10-28 2014-06-03 Ulrich Goepfert Protein expression in rodent cells
US20080045453A1 (en) * 2005-12-21 2008-02-21 Drohan William N Method of producing biologically active vitamin K dependent proteins by recombinant methods
WO2007081336A1 (en) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Mammalian vectors for high-level expression of recombinant proteins
JP4870208B2 (ja) 2006-05-17 2012-02-08 エフ．ホフマン−ラ ロシュ アーゲー ポリペプチド産生細胞
CA2656558A1 (en) * 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20090203077A1 (en) * 2006-06-30 2009-08-13 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
US20090143288A1 (en) * 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
EP1975228A1 (en) 2007-03-28 2008-10-01 Fachhochschule Mannheim Polynucleotides for enhancing expression of a polynucleotide of interest
EP2139499A4 (en) 2007-04-26 2010-05-05 Inspiration Biopharmaceuticals RECOMBINANT VITAMIN K-DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHOD FOR THE PRODUCTION THEREOF
EP3351557A1 (en) * 2007-06-29 2018-07-25 F. Hoffmann-La Roche AG Heavy chain mutant leading to improved immunoglobulin production
AU2008309934B2 (en) 2007-10-12 2014-03-06 F. Hoffmann-La Roche Ag Protein expression from multiple nucleic acids
US7892760B2 (en) 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
MX2010011672A (es) 2008-04-24 2011-03-02 Celtic Pharma Peg Ltd Conjugados del factor ix con vidas medias extendidas.
EP2282773B1 (en) 2008-05-02 2014-01-15 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
PL2462237T3 (pl) 2009-08-06 2016-06-30 Cmc Icos Biologics Inc Sposoby polepszania wyrażania białka rekombinowanego
EP2478107B1 (en) 2009-09-15 2018-08-29 Medimmune Limited Cells for transient expression and uses thereof
JP5851410B2 (ja) 2009-10-30 2016-02-03 シーエヌジェイ ホールディングス、インク． 組換えビタミンｋ依存性タンパク質の生成法
EP2339009A1 (en) 2009-12-22 2011-06-29 Sandoz Ag Cold inducible promoter sequences
WO2011123489A2 (en) 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
CA3017116A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
EP2753644A1 (en) 2011-09-09 2014-07-16 Universiteit Utrecht Holding B.V. Broadly neutralizing vhh against hiv-1
JP5775974B2 (ja) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
US9023995B2 (en) 2011-11-16 2015-05-05 Boehringer Ingelheim International Gmbh Anti IL-36R antibodies
MX355624B (es) 2011-12-22 2018-04-25 Hoffmann La Roche Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
SI2794878T1 (sl) 2011-12-22 2020-07-31 F. Hoffmann-La Roche Ag Organizacija ekspresijskega vektorja, postopki izdelave nove proizvodne celice in njihova uporaba za rekombinantno proizvodnjo polipeptidov
BR112014013035A2 (pt) 2011-12-22 2018-10-09 Hoffmann La Roche métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
CN108324943B (zh) 2012-02-10 2024-03-08 思进股份有限公司 Cd30+癌症的检测和治疗
CN104254603A (zh) * 2012-02-14 2014-12-31 博尔托拉制药公司 用于制备xa因子抑制剂的重组解毒剂的方法
ES2908474T3 (es) 2012-05-03 2022-04-29 Boehringer Ingelheim Int Anticuerpos anti-IL-23p19
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2922871B1 (en) 2012-11-20 2019-06-19 The University of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
NZ711654A (en) 2013-03-12 2021-07-30 Cmc Icos Biologics Inc Improved recombinant protein expression using a hybrid chef1 promoter
PE20152004A1 (es) 2013-03-13 2016-02-07 Prothena Biosciences Ltd Inmunoterapia tau
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015075635A2 (en) 2013-11-19 2015-05-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
CN105873949A (zh) 2014-01-31 2016-08-17 勃林格殷格翰国际有限公司 新的抗baff抗体
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
KR20160131082A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg1-3에 특이적인 항-라미닌4 항체
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718122B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10308705B2 (en) 2015-02-06 2019-06-04 The University Of North Carolina At Chapel Hill Optimized human clotting factor VIII gene expression cassettes and their use
MX2017013156A (es) 2015-04-14 2018-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades.
CA3022547A1 (en) 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
US11560418B2 (en) 2015-10-20 2023-01-24 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX fusion proteins
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
MX2018012410A (es) 2016-04-15 2019-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades inflamatorias.
ES2864211T3 (es) 2016-04-25 2021-10-13 Syntimmune Inc Anticuerpos anti-FcRn humanizados con maduración de la afinidad
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
KR102506091B1 (ko) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 타우 면역요법
CU24537B1 (es) 2016-05-02 2021-07-02 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478716A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
CN109790214B (zh) 2016-09-29 2022-09-06 豪夫迈·罗氏有限公司 用于选择产生多肽的细胞的改进方法
EP3848390A1 (en) 2016-10-14 2021-07-14 Boehringer Ingelheim International GmbH Methods of treating diseases
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
AU2018263935A1 (en) 2017-05-02 2019-12-19 Prothena Biosciences Limited Antibodies recognizing tau
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
WO2019064053A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
KR20200111198A (ko) 2018-01-10 2020-09-28 에이쥐씨 바이올로직스, 인크. 양방향성 chef1 벡터
US20210032316A1 (en) 2018-02-05 2021-02-04 Stichting Vu Inverse Agonistic Anti-US28 Antibodies
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
WO2019235923A1 (en) 2018-06-04 2019-12-12 Erasmus University Medical Center Rotterdam Role for low density lipoprotein receptor-related protein 10 in progressive brain diseases
EP3813950A1 (en) 2018-06-29 2021-05-05 Boehringer Ingelheim International GmbH Anti-cd40 antibodies for use in treating autoimmune disease
CN110904127A (zh) 2018-09-18 2020-03-24 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
KR20210094610A (ko) 2018-11-26 2021-07-29 포티 세븐, 인코포레이티드 c-Kit에 대한 인간화 항체
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
JP2022524588A (ja) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
EP3946434A1 (en) 2019-04-02 2022-02-09 Immunetune B.V. Immune-stimulatory compositions and use thereof
PE20220287A1 (es) 2019-05-09 2022-02-25 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
TW202115112A (zh) 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
TW202126685A (zh) 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
IL298431A (en) 2020-05-26 2023-01-01 Boehringer Ingelheim Int Anti-pd-1 antibodies
WO2022170008A2 (en) 2021-02-05 2022-08-11 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
US20230257455A1 (en) 2021-12-22 2023-08-17 Cdr-Life Ag Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
CN114540352A (zh) * 2022-02-16 2022-05-27 艾瑞生命科学技术(常州)有限公司 一种多核苷酸、载体元件及表达载体和宿主细胞及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3051411B2 (ja) * 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5266491A (en) * 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3501286B2 (ja) * 1989-12-22 2004-03-02 アプライド リサーチ システムズ，エーアールエス ホールディング ナームロゼ ベノートスハップ 一定の細胞系又は微生物の内因性遺伝子の発現特徴の変性のための方法
US5650294A (en) * 1990-06-25 1997-07-22 Basf Aktiengesellschaft Isolated promoter and terminator of elongation factor 1-α
EP0539573A4 (en) * 1991-05-15 1993-12-29 Cell Genesys, Inc. Genomic modifications with homologous dna targeting
CA2051085C (en) * 1991-09-10 2001-08-21 Shigekazu Nagata Expression plasmids
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2535871C1 (ru) * 2013-07-10 2014-12-20 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") Плазмида для экспрессии в клетке китайского хомячка, клетка китайского хомячка - продуцент белка с Gla-доменом и способ получения белка с Gla-доменом

Also Published As

Publication number Publication date
DE69833649T2 (de) 2006-12-28
HUP0004137A3 (en) 2003-08-28
CN100430477C (zh) 2008-11-05
CN1230991A (zh) 1999-10-06
SK11899A3 (en) 2000-05-16
PL195604B1 (pl) 2007-10-31
US5888809A (en) 1999-03-30
IL127897A (en) 2005-12-18
BR9804896B1 (pt) 2013-11-26
CZ296544B6 (cs) 2006-04-12
BR9804896A (pt) 1999-08-31
DE69833649D1 (de) 2006-04-27
HUP0004137A2 (en) 2001-03-28
SK285664B6 (sk) 2007-05-03
EP1676916A1 (en) 2006-07-05
NO323853B1 (no) 2007-07-16
PL331005A1 (en) 1999-06-21
RU2249617C2 (ru) 2005-04-10
ES2263206T3 (es) 2006-12-01
DK0920498T3 (da) 2006-07-10
HK1022719A1 (en) 2000-08-18
HU225764B1 (en) 2007-08-28
EP0920498B1 (en) 2006-03-01
AU7277098A (en) 1998-11-24
IL127897A0 (en) 1999-11-30
NO990025L (no) 1999-03-01
CN101570753A (zh) 2009-11-04
CZ28099A3 (cs) 2000-02-16
AU742561B2 (en) 2002-01-03
ATE318900T1 (de) 2006-03-15
NO990025D0 (no) 1999-01-04
JP2000513948A (ja) 2000-10-24
PT920498E (pt) 2006-08-31
WO1998049289A1 (en) 1998-11-05
EP0920498A1 (en) 1999-06-09

Similar Documents

Publication Publication Date Title
RU2004136574A (ru) Транскрипционная регуляторная днк гена хомяка ef-1
Hübel et al. Arabidopsis heat shock factor: isolation and characterization of the gene and the recombinant protein
RU99101788A (ru) ТРАНСКРИПЦИОННАЯ РЕГУЛИРУЮЩАЯ ДНК ГЕНА ХОМЯКА EF-1α
Hisatake et al. Cloning and structural analysis of cDNA and the gene for mouse transcription factor UBF
Haynes et al. The Drosophila Hrb98DE locus encodes four protein isoforms homologous to the A1 protein of mammalian heterogeneous nuclear ribonucleoprotein complexes
CA1341119C (en) Human erythroid-specific transcriptional enhancer
CA2935724C (en) Construct and sequence for enhanced gene expression
NZ225351A (en) Genetically engineered inducible virus resistance in plants
CA2304105A1 (en) Control pod dehiscence or shatter
DE69739524D1 (de) Dp-75 kodierende dna und verfahren zu ihrer verwendung
Caelles et al. The hydroxyproline-rich glycoprotein gene from Oryza sativa
US5981224A (en) Bovine heat shock promoter and uses thereof
KR970705923A (ko) LERK-6으로 명명된 시토킨(Cytokine Designated LERK-6)
HUP0102911A2 (hu) Indukálható promóterek
Kamata et al. Nucleotide sequence of cDNA to the rinderpest virus mRNA encoding the nucleocapsid protein
CA2045839A1 (en) Cloned n-methylhydantoinase
Paznekas et al. Mouse TCOF1 is expressed widely, has motifs conserved in nucleolar phosphoproteins, and maps to chromosome 18
Furia et al. A new gene nested within the dunce genetic unit of Drosophila melanogaster
Matsuda et al. Tissue‐specific isoforms of the bovine mitochondrial ATP synthase γ‐subunit
MX9206265A (es) Procedimiento biosintetico para la preparacion de compuestos quimicos.
Edlund et al. Structure of the human ϰ-casein gene
McDermott et al. Structure and lens expression of the gene encoding chicken βA3/A1-crystallin
CA2301902A1 (en) Novel extracellular serine protease
JP2019176833A (ja) レアアース種分離回収融合タンパク質及びその利用
RU99128056A (ru) Сосудистый белок-1 адгезии, обладающий аминоксидазной активностью

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090310